AIP4 Activators are a class of chemical compounds designed to modulate the activity of the Atrophin-1-interacting protein 4 (AIP4), also known as ITCH (for itchy E3 ubiquitin protein ligase homolog). AIP4/ITCH is a member of the HECT (homologous to E6-AP carboxyl terminus) domain-containing E3 ubiquitin ligase family. Ubiquitin ligases play a pivotal role in regulating protein stability by tagging target proteins with ubiquitin molecules, marking them for degradation by the proteasome or regulating their cellular localization and activity. AIP4/ITCH is involved in the ubiquitination and subsequent degradation of various protein substrates, making it an essential player in multiple cellular processes, including signal transduction, immune responses, and protein turnover. AIP4 Activators are synthesized to selectively interact with AIP4, influencing its ubiquitin ligase activity or its interactions with specific protein substrates, although the specific mechanisms can vary among different compounds within this chemical class.
The activation or modulation of AIP4 by these compounds can have far-reaching effects on cellular processes, depending on the protein substrates targeted for ubiquitination. AIP4/ITCH has been implicated in the ubiquitination and degradation of a diverse array of proteins, including signaling molecules like Notch, JunB, and c-Jun, as well as components of the immune system, such as the T-cell receptor and several cytokine receptors. By altering the ubiquitination patterns mediated by AIP4/ITCH, AIP4 Activators affect the stability and function of these target proteins, consequently influencing various cellular responses and pathways. These activators are valuable tools for scientists studying the regulation of protein turnover and the roles of ubiquitin ligases in cell signaling and immune responses.
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin destabilizes various client proteins, possibly enhancing the need for AIP4-mediated degradation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
By inhibiting JNK, SP600125 may alter signaling pathways that influence AIP4 activity or substrate specificity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, which can modify cellular responses, potentially affecting AIP4-mediated processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which can change signaling pathways, possibly influencing AIP4 activity indirectly. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB, potentially affecting AIP4's role in immune signaling and inflammation. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
3-MA inhibits autophagy, potentially increasing reliance on proteasomal degradation involving AIP4. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine inhibits lysosomal function, which might increase the role of proteasomal degradation via AIP4. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib, a tyrosine kinase inhibitor, may indirectly influence AIP4 activity through modulation of kinase signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, affecting various cellular processes, potentially impacting AIP4 activity. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Nifedipine, a calcium channel blocker, might indirectly affect pathways involving AIP4. |